Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells.

Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, Grohmann U.

Nat Immunol. 2011 Jul 31;12(9):870-8. doi: 10.1038/ni.2077.

PMID:
21804557
2.

Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation.

Fallarino F, Volpi C, Fazio F, Notartomaso S, Vacca C, Busceti C, Bicciato S, Battaglia G, Bruno V, Puccetti P, Fioretti MC, Nicoletti F, Grohmann U, Di Marco R.

Nat Med. 2010 Aug;16(8):897-902. doi: 10.1038/nm.2183. Epub 2010 Jul 25.

PMID:
20657581
3.

IDO mediates TLR9-driven protection from experimental autoimmune diabetes.

Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, Puccetti P, Romani L, Grohmann U.

J Immunol. 2009 Nov 15;183(10):6303-12. doi: 10.4049/jimmunol.0901577. Epub 2009 Oct 19. Erratum in: J Immunol. 2010 Jun 15;184(12):7316.

4.

Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone.

Fallarino F, Luca G, Calvitti M, Mancuso F, Nastruzzi C, Fioretti MC, Grohmann U, Becchetti E, Burgevin A, Kratzer R, van Endert P, Boon L, Puccetti P, Calafiore R.

J Exp Med. 2009 Oct 26;206(11):2511-26. doi: 10.1084/jem.20090134. Epub 2009 Oct 12.

5.

SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis.

Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Grohmann U, Puccetti P.

Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20828-33. doi: 10.1073/pnas.0810278105. Epub 2008 Dec 16.

6.

Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells.

Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT, Boon L, Gizzi S, Fioretti MC, Grohmann U, Puccetti P.

J Immunol. 2008 Oct 15;181(8):5194-8.

7.

Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease.

Romani L, Fallarino F, De Luca A, Montagnoli C, D'Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti MC, Grohmann U, Segal BH, Puccetti P.

Nature. 2008 Jan 10;451(7175):211-5. doi: 10.1038/nature06471.

PMID:
18185592
8.

Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes.

Belladonna ML, Puccetti P, Orabona C, Fallarino F, Vacca C, Volpi C, Gizzi S, Pallotta MT, Fioretti MC, Grohmann U.

Transplantation. 2007 Jul 15;84(1 Suppl):S17-20.

PMID:
17632406
9.

Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy.

Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna ML, Ayroldi E, Nocentini G, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti P.

Nat Med. 2007 May;13(5):579-86. Epub 2007 Apr 8.

PMID:
17417651
10.

Tryptophan catabolism generates autoimmune-preventive regulatory T cells.

Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Fioretti MC, Puccetti P.

Transpl Immunol. 2006 Dec;17(1):58-60. Epub 2006 Oct 10.

PMID:
17157218
11.

Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO.

Belladonna ML, Grohmann U, Guidetti P, Volpi C, Bianchi R, Fioretti MC, Schwarcz R, Fallarino F, Puccetti P.

J Immunol. 2006 Jul 1;177(1):130-7.

12.

IL-23 neutralization protects mice from Gram-negative endotoxic shock.

Belladonna ML, Vacca C, Volpi C, Giampietri A, Fioretti MC, Puccetti P, Grohmann U, Campanile F.

Cytokine. 2006 May;34(3-4):161-9. Epub 2006 Jun 8.

PMID:
16759878
13.

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.

Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P.

J Immunol. 2006 Jun 1;176(11):6752-61.

14.

Toward the identification of a tolerogenic signature in IDO-competent dendritic cells.

Orabona C, Puccetti P, Vacca C, Bicciato S, Luchini A, Fallarino F, Bianchi R, Velardi E, Perruccio K, Velardi A, Bronte V, Fioretti MC, Grohmann U.

Blood. 2006 Apr 1;107(7):2846-54. Epub 2005 Dec 8. Erratum in: Blood. 2006 May 1;107(9):3441.

PMID:
16339401
15.

Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12.

Orabona C, Tomasello E, Fallarino F, Bianchi R, Volpi C, Bellocchio S, Romani L, Fioretti MC, Vivier E, Puccetti P, Grohmann U.

Eur J Immunol. 2005 Nov;35(11):3111-8.

16.

Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells.

Fallarino F, Orabona C, Vacca C, Bianchi R, Gizzi S, Asselin-Paturel C, Fioretti MC, Trinchieri G, Grohmann U, Puccetti P.

Int Immunol. 2005 Nov;17(11):1429-38. Epub 2005 Sep 19.

PMID:
16172135
17.

CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig.

Vacca C, Fallarino F, Perruccio K, Orabona C, Bianchi R, Gizzi S, Velardi A, Fioretti MC, Puccetti P, Grohmann U.

Microbes Infect. 2005 Jun;7(7-8):1040-8.

PMID:
15925532
18.

Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant.

Orabona C, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Volpi C, Gizzi S, Fioretti MC, Grohmann U, Puccetti P.

J Immunol. 2005 Jun 1;174(11):6582-6.

19.

CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice.

Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, Serreze DV, Grohmann U, Puccetti P.

J Exp Med. 2004 Oct 18;200(8):1051-62.

20.

CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86.

Orabona C, Grohmann U, Belladonna ML, Fallarino F, Vacca C, Bianchi R, Bozza S, Volpi C, Salomon BL, Fioretti MC, Romani L, Puccetti P.

Nat Immunol. 2004 Nov;5(11):1134-42. Epub 2004 Oct 3.

PMID:
15467723
21.

Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement.

Fallarino F, Asselin-Paturel C, Vacca C, Bianchi R, Gizzi S, Fioretti MC, Trinchieri G, Grohmann U, Puccetti P.

J Immunol. 2004 Sep 15;173(6):3748-54.

22.

T cell apoptosis by kynurenines.

Fallarino F, Grohmann U, Vacca C, Orabona C, Spreca A, Fioretti MC, Puccetti P.

Adv Exp Med Biol. 2003;527:183-90.

PMID:
15206731
23.

Tryptophan catabolism in nonobese diabetic mice.

Grohmann U, Fallarino F, Bianchi R, Vacca C, Orabona C, Belladonna ML, Fioretti MC, Puccetti P.

Adv Exp Med Biol. 2003;527:47-54.

PMID:
15206715
24.

Modulation of tryptophan catabolism by regulatory T cells.

Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P.

Nat Immunol. 2003 Dec;4(12):1206-12. Epub 2003 Oct 26.

PMID:
14578884
25.

Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation.

Grohmann U, Bianchi R, Orabona C, Fallarino F, Vacca C, Micheletti A, Fioretti MC, Puccetti P.

J Immunol. 2003 Sep 1;171(5):2581-7.

26.

A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice.

Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, Puccetti P.

J Exp Med. 2003 Jul 7;198(1):153-60. Epub 2003 Jun 30.

27.

CTLA-4-Ig regulates tryptophan catabolism in vivo.

Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P.

Nat Immunol. 2002 Nov;3(11):1097-101. Epub 2002 Sep 30.

PMID:
12368911
28.

T cell apoptosis by tryptophan catabolism.

Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P.

Cell Death Differ. 2002 Oct;9(10):1069-77.

29.

CD40 ligand and CTLA-4 are reciprocally regulated in the Th1 cell proliferative response sustained by CD8(+) dendritic cells.

Fallarino F, Grohmann U, Vacca C, Bianchi R, Fioretti MC, Puccetti P.

J Immunol. 2002 Aug 1;169(3):1182-8.

30.

IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells.

Belladonna ML, Renauld JC, Bianchi R, Vacca C, Fallarino F, Orabona C, Fioretti MC, Grohmann U, Puccetti P.

J Immunol. 2002 Jun 1;168(11):5448-54.

31.

Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells.

Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B, Keskin DB, Mellor AL, Fioretti MC, Grohmann U, Puccetti P.

Int Immunol. 2002 Jan;14(1):65-8.

PMID:
11751753
32.

IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase.

Grohmann U, Fallarino F, Bianchi R, Belladonna ML, Vacca C, Orabona C, Uyttenhove C, Fioretti MC, Puccetti P.

J Immunol. 2001 Jul 15;167(2):708-14.

33.

Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma.

Grohmann U, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Orabona C, Fioretti MC, Puccetti P.

J Immunol. 2001 Jul 1;167(1):221-7.

34.

[Cystic parathyroid adenoma of the mediastinum with primary hyperparathyroidism. Report of a case].

Tonolini M, Fioretti MC, Mazzoleni C, Bastagli A, Cornalba G.

Radiol Med. 2000 Jun;99(6):491-4. Italian. No abstract available.

PMID:
11262836
35.

IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10.

Grohmann U, Van Snick J, Campanile F, Silla S, Giampietri A, Vacca C, Renauld JC, Fioretti MC, Puccetti P.

J Immunol. 2000 Apr 15;164(8):4197-203.

36.

CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells.

Grohmann U, Fallarino F, Silla S, Bianchi R, Belladonna ML, Vacca C, Micheletti A, Fioretti MC, Puccetti P.

J Immunol. 2001 Jan 1;166(1):277-83.

37.

Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo.

Fallarino F, Grohmann U, Bianchi R, Vacca C, Fioretti MC, Puccetti P.

J Immunol. 2000 Nov 15;165(10):5495-501.

38.

IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subset.

Grohmann U, Bianchi R, Belladonna ML, Silla S, Fallarino F, Fioretti MC, Puccetti P.

J Immunol. 2000 Aug 1;165(3):1357-63.

39.

Dual effect of IL-4 on resistance to systemic gram-negative infection and production of TNF-alpha.

Giampietri A, Grohmann U, Vacca C, Fioretti MC, Puccetti P, Campanile F.

Cytokine. 2000 Apr;12(4):417-21.

PMID:
10805227
40.

IL-12 induces SDS-stable class II alphabeta dimers in murine dendritic cells.

Grohmann U, Orabona C, Bianchi R, Belladonna ML, Fioretti MC, Puccetti P.

Cytokine. 2000 Apr;12(4):401-4.

PMID:
10805223
41.

IL-12 acts selectively on CD8 alpha- dendritic cells to enhance presentation of a tumor peptide in vivo.

Grohmann U, Bianchi R, Belladonna ML, Vacca C, Silla S, Ayroldi E, Fioretti MC, Puccetti P.

J Immunol. 1999 Sep 15;163(6):3100-5.

42.

Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation.

Bianchi R, Grohmann U, Vacca C, Belladonna ML, Fioretti MC, Puccetti P.

J Immunol. 1999 Sep 1;163(5):2517-21.

43.

Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex.

Grohmann U, Belladonna ML, Bianchi R, Orabona C, Silla S, Squillacioti G, Fioretti MC, Puccetti P.

Cancer Immunol Immunother. 1999 Jul;48(4):195-203.

PMID:
10431689
44.

IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production.

Grohmann U, Belladonna ML, Bianchi R, Orabona C, Ayroldi E, Fioretti MC, Puccetti P.

Immunity. 1998 Sep;9(3):315-23.

45.

The role of IL-12 in the induction of an immune response to a tumor/self peptide: prevention and reversion of anergy.

Belladonna ML, Grohmann U, Bianchi R, Ayroldi E, Surace D, Puccetti P, Fioretti MC.

J Chemother. 1998 Apr;10(2):157-9. No abstract available.

PMID:
9603645
46.

Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide.

Grohmann U, Fioretti MC, Bianchi R, Belladonna ML, Ayroldi E, Surace D, Silla S, Puccetti P.

Crit Rev Immunol. 1998;18(1-2):87-98. Review.

PMID:
9419451
47.

Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.

Grohmann U, Silla S, Belladonna ML, Bianchi R, Orabona C, Puccetti P, Fioretti MC.

Cell Immunol. 1997 Nov 1;181(2):109-19.

PMID:
9398398
48.

A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state.

Grohmann U, Bianchi R, Ayroldi E, Belladonna ML, Surace D, Fioretti MC, Puccetti P.

J Immunol. 1997 Apr 15;158(8):3593-602.

PMID:
9103420
49.

[Occult perineural cysts in a case of Von Recklinghausen disease. Report of a case].

Bonfanti MT, Fioretti MC, Rispoli GA, Rizzato R, Russo P, Uslenghi CM.

Radiol Med. 1997 Jan-Feb;93(1-2):148-50. Italian. No abstract available.

PMID:
9380857
50.

Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines.

Grohmann U, Bianchi R, Belladonna ML, Silla S, Surace D, Fioretti MC, Puccetti P.

Adv Exp Med Biol. 1997;417:579-82. No abstract available.

PMID:
9286421

Supplemental Content

Loading ...
Support Center